Adamas to Present at Two Upcoming Investor Conferences

May 2, 2018 EMERYVILLE, Calif., May 02, 2018 (GLOBE NEWSWIRE) — Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that company management is scheduled to present at two upcoming investor conferences: Gregory T. Went, Ph.D., the company’s Founder, Chairman and Chief Executive Officer, is scheduled to

Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia

Apr 19, 2018 — Patients receiving GOCOVRI experienced long-term durability for up to two years — — Safety profile was consistent with previously-published controlled Phase 3 studies — EMERYVILLE, Calif., April 19, 2018 (GLOBE NEWSWIRE) — Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced positive data